What is HC Wainwright’s Estimate for I-Mab Q1 Earnings?

I-Mab (NASDAQ:NBP) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of I-Mab in a research report issued to clients and investors on Friday, February 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. HC Wainwright also issued estimates for I-Mab’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2030 earnings at $0.14 EPS.

A number of other equities research analysts have also commented on the company. Wall Street Zen raised I-Mab from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings initiated coverage on shares of I-Mab in a report on Thursday. They set a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, I-Mab currently has a consensus rating of “Hold” and a consensus target price of $9.00.

I-Mab Trading Up 11.1%

Shares of NASDAQ NBP opened at $3.70 on Monday. I-Mab has a twelve month low of $0.60 and a twelve month high of $6.79. The firm has a market cap of $426.57 million, a PE ratio of -10.28 and a beta of 1.62.

I-Mab (NASDAQ:NBP) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.07) EPS for the quarter.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.